UA81499C2 - Pharmaceutical composition containing histone deacetylase inhibitor - Google Patents

Pharmaceutical composition containing histone deacetylase inhibitor

Info

Publication number
UA81499C2
UA81499C2 UAA200512454A UAA200512454A UA81499C2 UA 81499 C2 UA81499 C2 UA 81499C2 UA A200512454 A UAA200512454 A UA A200512454A UA A200512454 A UAA200512454 A UA A200512454A UA 81499 C2 UA81499 C2 UA 81499C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
composition containing
histone deacetylase
deacetylase inhibitor
containing histone
Prior art date
Application number
UAA200512454A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UA81499C2 publication Critical patent/UA81499C2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
UAA200512454A 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor UA81499C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26
PCT/JP2004/007562 WO2004103369A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Publications (1)

Publication Number Publication Date
UA81499C2 true UA81499C2 (en) 2008-01-10

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200512454A UA81499C2 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Country Status (27)

Country Link
US (1) US20070098816A1 (xx)
EP (1) EP1626719A1 (xx)
JP (1) JP2006526031A (xx)
KR (1) KR100938712B1 (xx)
CN (2) CN1794991A (xx)
AR (1) AR045318A1 (xx)
AU (1) AU2004241873C1 (xx)
BR (1) BRPI0410959A (xx)
CA (4) CA2527191A1 (xx)
CL (1) CL2004001278A1 (xx)
CO (1) CO5660262A2 (xx)
CR (1) CR8163A (xx)
CU (1) CU23490B7 (xx)
EC (1) ECSP056253A (xx)
IL (1) IL171941A0 (xx)
ME (1) MEP32308A (xx)
MX (1) MXPA05012345A (xx)
NO (1) NO20055417L (xx)
NZ (1) NZ543591A (xx)
PE (1) PE20050206A1 (xx)
RS (1) RS20050884A (xx)
RU (1) RU2322971C2 (xx)
TW (1) TW200505424A (xx)
UA (1) UA81499C2 (xx)
UY (1) UY28330A1 (xx)
WO (1) WO2004103369A1 (xx)
ZA (1) ZA200509515B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
AU2006223086A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
WO2006102557A2 (en) 2005-03-22 2006-09-28 The President And Fellows Of Harvard College Treatment of protein degradation disorders
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
CN101528679A (zh) 2006-02-14 2009-09-09 哈佛大学校长及研究员协会 组蛋白去乙酰化酶抑制剂
CN101400362B (zh) 2006-02-14 2016-10-12 哈佛大学校长及研究员协会 双官能组蛋白去乙酰化酶抑制剂
CA2654540C (en) 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
ES2529147T3 (es) * 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
CA2709383A1 (en) * 2007-12-14 2009-06-25 Milton L. Brown Histone deacetylase inhibitors
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
PT2350005E (pt) * 2008-08-29 2012-03-12 Bayer Pharma AG Polimorfo b de n-(2-aminofenil)-4-[n-(piridina-3-il)¿ metoxicarbonil-aminometil]-benzamida (ms-275)
SG10201607592PA (en) 2008-12-19 2016-11-29 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase
WO2010093561A1 (en) * 2009-02-11 2010-08-19 Liangping Yu Particulate composition and the method of making the same
CA2758856A1 (en) * 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
CN102459159A (zh) * 2009-06-08 2012-05-16 吉利德科学股份有限公司 烷酰基氨基苯甲酰胺苯胺hdac抑制剂化合物
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
SG178873A1 (en) * 2009-08-25 2012-04-27 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
CA2798763A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
EP2940017B1 (en) 2011-09-30 2019-08-28 Vertex Pharmaceuticals Incorporated Process for making compounds useful as inhibitors of ATR kinase
WO2013049859A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
WO2014164708A1 (en) * 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
US9963452B2 (en) * 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
EA201592012A8 (ru) * 2014-02-21 2018-10-31 Общество С Ограниченной Ответственностью "Биолаб 612" Применение флагеллина для улучшенной химиотерапии
KR20170048601A (ko) 2014-09-17 2017-05-08 셀젠 콴티셀 리서치, 인크. 히스톤 탈메틸효소 억제제
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
JP3354090B2 (ja) 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
AP2001002109A0 (en) * 1998-09-25 2001-03-31 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
WO2000064478A1 (fr) * 1999-04-27 2000-11-02 Mitsubishi Pharma Corporation Medicaments destines a soigner et a prevenir les maladies du foie
CN1387438A (zh) * 1999-11-10 2002-12-25 沃尼尔·朗伯公司 联合化学疗法
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
CA2634709A1 (en) 2004-12-02
AU2004241873C1 (en) 2009-01-22
TW200505424A (en) 2005-02-16
ECSP056253A (es) 2006-10-25
CN1794991A (zh) 2006-06-28
EP1626719A1 (en) 2006-02-22
RS20050884A (xx) 2008-04-04
CU23490B7 (es) 2010-02-23
ZA200509515B (en) 2006-07-26
NZ543591A (en) 2009-09-25
AU2004241873B2 (en) 2008-05-08
WO2004103369A1 (en) 2004-12-02
CA2634766A1 (en) 2004-12-02
CA2634765A1 (en) 2004-12-02
AU2004241873A1 (en) 2004-12-02
AU2004241873B8 (en) 2008-05-29
US20070098816A1 (en) 2007-05-03
PE20050206A1 (es) 2005-03-26
RU2005140570A (ru) 2006-06-10
JP2006526031A (ja) 2006-11-16
CL2004001278A1 (es) 2005-05-06
CN101322707A (zh) 2008-12-17
KR100938712B1 (ko) 2010-01-25
AR045318A1 (es) 2005-10-26
CR8163A (es) 2006-07-14
MXPA05012345A (es) 2006-02-08
BRPI0410959A (pt) 2006-07-04
NO20055417D0 (no) 2005-11-16
RU2322971C2 (ru) 2008-04-27
CO5660262A2 (es) 2006-07-31
NO20055417L (no) 2005-12-19
CA2527191A1 (en) 2004-12-02
UY28330A1 (es) 2004-12-31
KR20060009371A (ko) 2006-01-31
IL171941A0 (en) 2006-04-10
MEP32308A (en) 2010-10-10

Similar Documents

Publication Publication Date Title
TW200505424A (en) Pharmaceutical composition containing histone deacetylase inhibitor
NO20055216D0 (no) Nye hydroksamater som terapeutiske midler
BR0308081A (pt) Inibidores de histona desacetilase
PL371100A1 (en) Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
PL370982A1 (en) Carbonylamino-derivatives as novel inhibitors of histone deacetylase
PL371036A1 (en) Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
MXPA06000013A (es) Agente terapeutico para sarcoma de tejido suave.
EA200801492A1 (ru) Фармацевтическое применение замещенных амидов
MY142177A (en) Benzamide derivatives useful as histone deacetylase inhibitors
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
EA200700143A1 (ru) Производные замещенного пропенилпиперазина в качестве новых ингибиторов гистондеацетилазы
GB2427405A (en) Novel hydroxamates as therapeutic agents
WO2008101907A3 (en) N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
WO2006063294A3 (en) Novel inhibitors of histone deacetylase for the treatment of disease
ZA200708749B (en) Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
TW200638927A (en) Bambuterol and integrin inhibitor combination
PA8633001A1 (es) Composicion farmaceutica antimicobacterial
MX2008008470A (es) Nuevos derivados pirrolicos con actividad inhibidora de desacetilasa de histonas.
TH81162A (th) สารผสมทางเภสัชกรรมที่มีตัวยับยั้งฮิสโตนดีอะซีทิลเลส
TH81162B (th) สารผสมทางเภสัชกรรมที่มีตัวยับยั้งฮิสโตนดีอะซีทิลเลส
MY140524A (en) Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase